Paul A. Calvo, Ph.D., is quoted in Law360’s “”4 Questions After Amgen-Sandoz Rehearing Bids Fizzle Out,”” discussing the Federal Circuit’s panel decision to exempt biosimilar makers from exchanging intellectual property information with brand-name rivals, also known as “”the patent dance.””

“”Something that is open is: If you do the patent dance, maybe you don’t even need to provide notice of commercial marketing,”” said Calvo. “”That’s just hanging out there in the wind.””

For more information regarding the Federal Circuit’s decision, visit

Related Professionals